ZBTB43

Across TCGA pan-cancer cohorts, ZBTB43 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZBTB43 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ZBTB43 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZBTB43 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and PRAD are the cancer types where ZBTB43 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.268	0.802	.010	12	view →
UCEC	DFS	Median	All	0.939	0.625	.025	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	All	0.201	0.720	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZBTB43–ACC (OS)

Open the ACC breakdown →